Sign In
Buy LFCR
$4.42
+0.0600 (+1.38%)
At Close: Jul 31, 2026
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
07:00am, Tuesday, 28'th Oct 2025
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
07:00am, Monday, 13'th Oct 2025
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term st
Lifecore Biomedical (LFCR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:01am, Friday, 26'th Sep 2025
Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 23'rd Sep 2025
CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today a
Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?
10:11am, Friday, 12'th Sep 2025
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Lifecore Biomedical, Inc. (LFCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
07:07pm, Tuesday, 09'th Sep 2025
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Paul Josephs - President, CEO & Director Conference
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
04:05pm, Thursday, 04'th Sep 2025
CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today
Lifecore Biomedical to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 02'nd Sep 2025
CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
09:16am, Friday, 08'th Aug 2025
Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Part
Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates
08:36pm, Thursday, 07'th Aug 2025
Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
04:05pm, Thursday, 07'th Aug 2025
-- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance ; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflectin
Laughing Water Capital's Top 5 Positions For Q2 2025
04:45am, Thursday, 07'th Aug 2025
Lifecore Biomedical is positioned for margin expansion and likely acquisition, supported by industry trends and potential M&A multiples above current share price. NextNav is favorably placed for FCC s
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
04:05pm, Thursday, 31'st Jul 2025
CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
